Patents Examined by Anne Marie Wehbe?
-
Patent number: 7666639Abstract: This invention relates to pharmaceutical compositions comprising plant deoxyribonucleoside kinase enzymes (dNK) capable of phosphorylating nucleoside analogs and to medical use of said dNKs. More specifically the invention relates to the medical use of deoxyribonucleoside kinase enzymes derived from (Arabidopsis thaliana), from loblolly pine (Pinus taeda), from tomato (Lycopersicum esculentum), from maize (Zea mays) or from rice (Oryza sativa). The invention also relates to methods of sensitizing cells to prodrugs, and to methods of inhibiting pathogenic agents in warm-blooded animals using said plant dNKs. In another aspect the invention relates to plant derived deoxyribonucleoside kinase enzymes provided in isolated form from loblolly pine (Pinus taeda), from tomato (Lycopersicum esculentum), from maize (Zea mays) or from rice (Oryza sativa).Type: GrantFiled: June 24, 2003Date of Patent: February 23, 2010Inventors: Wolfgang Knecht, Birgitte Munch-Petersen, Jure Piskur
-
Patent number: 7629162Abstract: The present invention provides derivatives of ethanologenic Escherichia coli K011 constructed for the production of lactic acid. The transformed E. coli of the invention are prepared by deleting the genes that encode competing pathways followed by a growth-based selection for mutants with improved performance. These transformed E. coli are useful for providing an increased supply of lactic acid for use in food and industrial applications.Type: GrantFiled: August 8, 2006Date of Patent: December 8, 2009Assignee: University of Florida Research Foundation, Inc.Inventors: Shengde Zhou, Lonnie O'Neal Ingram, Keelnatham T. Shanmugam, Lorraine Yomano, Tammy B. Grabar, Jonathan C. Moore
-
Patent number: 7588936Abstract: The present invention is based on the discovery that teeth primordia can be generated using bone marrow cells and that bone marrow cells may be employed to generate teeth without the need for purification and expansion of a population of cells.Type: GrantFiled: February 17, 2004Date of Patent: September 15, 2009Assignee: Odontis Ltd.Inventor: Paul Thomas Sharpe
-
Patent number: 7462592Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: GrantFiled: October 22, 2002Date of Patent: December 9, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Patent number: 7459599Abstract: Transgenic silkworms comprising GFP whose expression is regulated by the sericin gene promoter were produced. Observation of the silk glands of the last instar larvae of the silkworms showed fluorescence only in the middle silk glands. GFP was secreted from middle silkgland cells from around the spinning stage, indicating that GFP moved into the gland lumen. Finally, GFP was spun into cocoon filaments, and cocoons containing large amounts of GFP were produced. Thus, by using the promoter region of the sericin gene, recombinant proteins can be produced in the middle silk glands. Furthermore, the recombinant proteins produced in the middle silk glands were readily secreted into the lumen of the middle silk glands.Type: GrantFiled: March 21, 2005Date of Patent: December 2, 2008Assignee: National Institute of Agrobiological SciencesInventors: Toshiki Tamura, Hideki Sezutsu, Isao Kobayashi, Katsura Kojima, Toshio Kanda, Keiro Uchino
-
Patent number: 7459540Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.Type: GrantFiled: August 23, 2000Date of Patent: December 2, 2008Assignee: Amgen Inc.Inventors: Arlen Thomason, Benxian Liu, Dimitry Michael Danilenko
-
Patent number: 7442768Abstract: The present invention provides a novel fluorescent protein the wavelength of the maximum of the fluorescence of which exists in a wavelength side longer than 510 nm, and which exhibits yellow fluorescence or yellowish green fluorescence and can be expressed in a heterogeneous cell, and a gene encoding the same, wherein the fluorescent protein has an amino acid sequence as set forth in SEQ ID NO:1and it is a fluorescent protein derived from a copepod taxonomically classified to Chiridius Poppei.Type: GrantFiled: September 30, 2004Date of Patent: October 28, 2008Assignees: NEC Soft, Ltd., National Institute of Agrobiochemical ScienceInventors: Frederick I. Tsuji, Hiroshi Mizuno, Kenji Takase, Mitsuru Momma, Zui Fujimoto, Toshiyuki Wako, Yasuhiro Takenaka, Noboru Nakura, Hiromi Takenaka
-
Patent number: 7442783Abstract: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.Type: GrantFiled: March 1, 2005Date of Patent: October 28, 2008Assignees: The CBR Institute for Biomedical Research, Inc., President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.Inventors: Michael C. Carroll, Francis D. Moore, Jr., Herbert B. Hechtman
-
Patent number: 7423194Abstract: This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.Type: GrantFiled: May 9, 2006Date of Patent: September 9, 2008Assignee: University of ChicagoInventors: Brian Popko, Wensheng Lin
-
Patent number: 7422736Abstract: The present invention discloses a cultured somatic animal cell having a normal karyotype; the cell develops into an embryoid body when induced in vitro, or develops into a teratoma when introduced into a SCID mouse. Also disclosed is a method of producing such a cell.Type: GrantFiled: November 4, 2002Date of Patent: September 9, 2008Assignee: Food Industry Research and Development InstituteInventor: Shiaw-Min Hwang
-
Patent number: 7413853Abstract: In accordance with the present invention, there are provided methods for modulating Phase II conjugating enzymes such as, for example, UGTs. Phase II conjugating enzymes such as UGTs function in concert with Phase I monooxygenase enzymes such as cytochrome P450 enzymes (CYPs) to eliminate steroids and xenobiotics. Nuclear receptors SXR/PXR and CAR are xenosensors regulating expression of CYP genes such as CYP3A and 2B. The ability of this group of receptors to regulate expression of UGT in response to steroids and/or xenobiotics provides novel approaches for direct regulation/activation of a glucuronidation pathway, thereby providing methods to achieve physiologic homeostasis with respect to steroids and/or xenobiotics. SXR/PXR and CAR regulation/activation of UGT represents the first evidence of receptors that can transduce/transactivate both Phase I and Phase II adaptive hepatic response. In another aspect, the present invention also provides transgenic rodents expressing one or more of SXR, CAR or PXR.Type: GrantFiled: July 9, 2002Date of Patent: August 19, 2008Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Wen Xie
-
Patent number: 7405287Abstract: The present invention provides isolated nucleic acids encoding delta DNA methyltransferase 3B molecules that are involved in the treatment and prevention of cancers such as, but not limited to, lung cancer. The delta DNA methyltransferase 3B molecules of the present invention are found to play a critical role in promoter-specific methylation of tumor suppressor genes. The DNA methyltransferase 3B molecules of the present invention are provided as therapeutic targets for identifying inhibitors of DNA methyltransferase. Such inhibitors are contemplated for the treatment and/or prevention of cancers. In particular embodiments, the present invention involves the treatment and prevention of a non-small cell lung cancer.Type: GrantFiled: July 26, 2005Date of Patent: July 29, 2008Assignee: Board of Regents, The University of Texas SystemInventors: Li Mao, Jie Wang, Luo Wang
-
Patent number: 7402729Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.Type: GrantFiled: June 14, 2005Date of Patent: July 22, 2008Assignee: Kirin Pharma Kabushiki KaishaInventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
-
Patent number: 7396904Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.Type: GrantFiled: November 29, 2004Date of Patent: July 8, 2008Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Hans Georg Rammensee, Stefan Stevanovic
-
Patent number: 7393525Abstract: A method for introducing and expressing genes in animal cells is disclosed comprising infecting said the animal cells with live invasive bacteria, wherein bacteria contain a eukaryotic expression cassette encoding said gene. The gene may encode, e.g., a vaccine antigen, an therapeutic agent, an immunoregulatory agent or a anti-sense RNA or a catalytic RNA.Type: GrantFiled: February 21, 2003Date of Patent: July 1, 2008Assignee: University of Maryland, BaltimoreInventors: Robert J. Powell, George K. Lewis, David M. Hone
-
Patent number: 7378277Abstract: Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.Type: GrantFiled: June 26, 2003Date of Patent: May 27, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Patrick Hwu, Mark Reeves, Steven A. Rosenberg
-
Patent number: 7374937Abstract: The invention includes in vitro methods of inducing and enhancing proliferation of human marrow stromal cells for use in, for example, gene therapy and transplantation methods. The invention also includes a method of assessing the expandability (i.e., proliferative capacity) of human marrow stromal cells. In addition, the invention includes a conditioned medium for enhancing proliferation of human marrow stromal cells.Type: GrantFiled: October 25, 2000Date of Patent: May 20, 2008Assignee: Philadelphia Health and Education CorporationInventors: Darwin J. Prockop, David Colter, Carla DiGirolamo
-
Patent number: 7371920Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: GrantFiled: June 19, 2001Date of Patent: May 13, 2008Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Patent number: 7371539Abstract: This invention pertains to compositions, methods, cells and organisms useful for selectively localizing polypeptides to the proteasome for degradation. Therapeutic methods and pharmaceutical compositions for treating disorders associated with the expression and/or activity of a polypeptide by targeting these polypeptides for degradation, as well as methods for targeting therapeutic polypeptides for degradation and/or activating therapeutic polypeptides by degradation are provided. The invention provides methods for identifying compounds that mediate proteasome localization and/or polypeptide degradation. The invention also provides research tools for the study of protein function.Type: GrantFiled: December 3, 2004Date of Patent: May 13, 2008Assignee: President and Fellows of Harvard CollegeInventors: George M. Church, Daniel M. Janse
-
Patent number: 7368532Abstract: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and is not a fragment or derivative of a HN domain of a clostridial toxin.Type: GrantFiled: December 4, 2000Date of Patent: May 6, 2008Assignee: Syntaxin LimitedInventors: Clifford Charles Shone, John Mark Sutton, Nigel Silman